SK287670B6 - Imunogénna lipozómová kompozícia a spôsob jej výroby - Google Patents

Imunogénna lipozómová kompozícia a spôsob jej výroby Download PDF

Info

Publication number
SK287670B6
SK287670B6 SK322-2001A SK3222001A SK287670B6 SK 287670 B6 SK287670 B6 SK 287670B6 SK 3222001 A SK3222001 A SK 3222001A SK 287670 B6 SK287670 B6 SK 287670B6
Authority
SK
Slovakia
Prior art keywords
liposome composition
immunogenic liposome
immunogenic
antigenic
protein
Prior art date
Application number
SK322-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK3222001A3 (en
Inventor
Gary Fujii
Donald V. Cramer
William A. Ernst
Jill Adler-Moore
L. Jeanne Perry
Original Assignee
Molecular Express, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Express, Inc. filed Critical Molecular Express, Inc.
Publication of SK3222001A3 publication Critical patent/SK3222001A3/sk
Publication of SK287670B6 publication Critical patent/SK287670B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SK322-2001A 1998-09-22 1999-09-22 Imunogénna lipozómová kompozícia a spôsob jej výroby SK287670B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10135198P 1998-09-22 1998-09-22
US40072399A 1999-09-21 1999-09-21
PCT/US1999/020880 WO2000016746A2 (en) 1998-09-22 1999-09-22 Immunogenic liposome compositions

Publications (2)

Publication Number Publication Date
SK3222001A3 SK3222001A3 (en) 2001-09-11
SK287670B6 true SK287670B6 (sk) 2011-05-06

Family

ID=26798150

Family Applications (1)

Application Number Title Priority Date Filing Date
SK322-2001A SK287670B6 (sk) 1998-09-22 1999-09-22 Imunogénna lipozómová kompozícia a spôsob jej výroby

Country Status (31)

Country Link
EP (1) EP1115382B1 (ja)
JP (1) JP2002526436A (ja)
KR (1) KR100592825B1 (ja)
CN (1) CN1555254A (ja)
AP (1) AP2010A (ja)
AT (1) ATE468108T1 (ja)
AU (1) AU766772B2 (ja)
BG (1) BG65675B1 (ja)
BR (1) BR9914004A (ja)
CA (1) CA2344173C (ja)
CY (1) CY1110718T1 (ja)
CZ (1) CZ20011013A3 (ja)
DE (1) DE69942393D1 (ja)
DK (1) DK1115382T3 (ja)
EA (1) EA004797B1 (ja)
EE (1) EE200100168A (ja)
ES (1) ES2345695T3 (ja)
GE (1) GEP20053444B (ja)
HK (1) HK1039064A1 (ja)
HU (1) HUP0105391A3 (ja)
ID (1) ID29082A (ja)
IL (2) IL141675A0 (ja)
MX (1) MXPA01002973A (ja)
NO (1) NO330685B1 (ja)
NZ (2) NZ528055A (ja)
OA (1) OA11657A (ja)
PL (1) PL206260B1 (ja)
SK (1) SK287670B6 (ja)
UA (1) UA75327C2 (ja)
WO (1) WO2000016746A2 (ja)
ZA (1) ZA200101829B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
KR102185682B1 (ko) 2009-06-04 2020-12-11 고쿠리츠칸센쇼켄쿠죠 마이코플라즈마 감염증용 백신
CA2834349A1 (en) 2011-04-26 2012-11-01 Molecular Express, Inc. Liposomal formulations
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
CA3057715A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
KR20240033309A (ko) * 2022-09-05 2024-03-12 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
SE462375B (sv) * 1985-10-15 1990-06-18 Morgaardshammar Ab Centro Traadblock
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires

Also Published As

Publication number Publication date
OA11657A (en) 2004-12-08
KR100592825B1 (ko) 2006-06-23
NO330685B1 (no) 2011-06-06
CA2344173A1 (en) 2000-03-30
AU6035199A (en) 2000-04-10
ZA200101829B (en) 2002-06-05
EP1115382A2 (en) 2001-07-18
PL206260B1 (pl) 2010-07-30
IL141675A (en) 2007-06-17
EP1115382B1 (en) 2010-05-19
AU766772B2 (en) 2003-10-23
WO2000016746A3 (en) 2000-11-23
NZ528055A (en) 2005-01-28
KR20010075261A (ko) 2001-08-09
BR9914004A (pt) 2001-07-24
CN1555254A (zh) 2004-12-15
HUP0105391A3 (en) 2006-02-28
WO2000016746A9 (en) 2000-09-21
DE69942393D1 (de) 2010-07-01
HUP0105391A2 (hu) 2002-05-29
NO20011406L (no) 2001-04-24
DK1115382T3 (da) 2010-09-06
MXPA01002973A (es) 2003-03-27
HK1039064A1 (en) 2002-04-12
BG65675B1 (bg) 2009-06-30
NO20011406D0 (no) 2001-03-20
AP2010A (en) 2009-06-29
NZ510442A (en) 2003-10-31
EE200100168A (et) 2002-06-17
WO2000016746A2 (en) 2000-03-30
CY1110718T1 (el) 2015-06-10
EA200100269A1 (ru) 2001-12-24
AP2001002096A0 (en) 2001-03-31
ID29082A (id) 2001-07-26
UA75327C2 (en) 2006-04-17
JP2002526436A (ja) 2002-08-20
IL141675A0 (en) 2002-03-10
ATE468108T1 (de) 2010-06-15
SK3222001A3 (en) 2001-09-11
EA004797B1 (ru) 2004-08-26
WO2000016746A8 (en) 2000-08-10
GEP20053444B (en) 2005-02-25
CA2344173C (en) 2010-02-23
PL348604A1 (en) 2002-06-03
BG105372A (en) 2001-10-31
ES2345695T3 (es) 2010-09-29
CZ20011013A3 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
US5880104A (en) Nucleic acid respiratory syncytial virus vaccines
Fayolle et al. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes.
JP3602448B2 (ja) 核酸呼吸器シンシチウムウイルスワクチン
RU2211050C2 (ru) Вакцины с адъювантом ltb
US6558673B1 (en) Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule
JP2000505299A (ja) 合成ｈｉｖ遺伝子
JPH07505412A (ja) Ｃｔｌ応答の誘導
SK287670B6 (sk) Imunogénna lipozómová kompozícia a spôsob jej výroby
EP1123711B9 (en) Attenuated toxins as adjuvants
CA1337115C (en) Vaccination against rabies-related diseases
US7588764B2 (en) Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles
US20020106376A1 (en) Therapeutic or prophylactic composition of fibronectin-binding protein 1 (SFBI) as adjuvant
Levi A synthetic approach to influenza vaccines
AU2136488A (en) Vaccination against rabies-related viruses

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120922